Showing 541-550 of 3410 results for "".
Part 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benValeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicDriving Growth in the Dermatology Practice
https://practicaldermatology.com/topics/practice-management/driving-growth-in-the-dermatology-practice/18630/Robert Rullo reminds dermatologists to think beyond being just a clinician and to remember they are also running a business. He discusses key business philosophies clinicians need to be aware of and common obstacles that inhibit geometric practice growth. Generations“No Drug is 100 Percent.”
https://practicaldermatology.com/conferences/maui-derm-2024/no-drug-is-100-percent/20242/Jason Hawkes, MD and Chief Medical Editor Neal Bhatia, MD discuss how the current array of options for patients of chronic spontaneous urticaria (CSU) expand treatment options for hives beyond antihistamines.The Science Driving Topicals Into the Future
https://practicaldermatology.com/topics/psoriasis/the-science-driving-topicals-into-the-future/19721/On the therapeutic front, one topic Neal Bhatia, MD is paying particularly close attention to is recent advances in vehicle science, which offer novel and intriguing strategies to improve delivery of topical applications to and through the skin.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.UCB: Committed to Driving Immuno-Dermatology Forward
https://practicaldermatology.com/topics/psoriasis/ucb-committed-to-driving-immuno-dermatology-forward-1/23361/New in My Practice: Cosmeceuticals
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-cosmeceuticals-1/23508/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21885/Currents
https://practicaldermatology.com/topics/practice-management/currents/21190/Speak Up! Advocate for yourself, your patients, your specialty